Search clinical trials for: JNJ-56136379

Total 1091 results

Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis (ICONIC-LEAD)

Plaque Psoriasis

Germany, United States, Hungary, Italy, Turkey, Korea, Republic of, United Kingdom, China, Taiwan, Poland, Canada, France, Australia, Spain, Argentina, Japan
Janssen Research & Development, LLC

Completed

A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis (SUMMIT)

Plaque Psoriasis

United States, Canada, Germany, France, Spain, Poland
Herbert Meltzer
Janssen Research & Development, LLC

Completed

Testing the Ability of JNJ-18038683 to Improve Cognition and Reduce Depressive Symptoms in Stable Bipolar Patients

Bipolar Disorder

United States
Janssen Research & Development, LLC

Withdrawn

A Study to Assess the Pharmacokinetics and Pharmacodynamics of JNJ-54452840 in Participants With Heart Failure and Anti-beta1-adrenergic Receptor Autoantibodies

Heart Failure
Janssen Research & Development, LLC

Active, not recruiting

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

Multiple Myeloma

Canada, United States, Germany, Netherlands, Spain
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

A Study of the Histone-deacetylase Inhibitor JNJ-26481585 in Patients With Advanced or Refractory Leukemia or Myelodysplastic Syndrome

Myelodysplastic Syndromes | Advanced or Refractory Leukemia

United States
Johnson & Johnson Pharmaceutical Research & Development...
Janssen Pharmaceutica N.V., Belgium

Completed

A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.

Pharmacokinetics | Advanced Malignancies | Solid Malignancies | Protein Kinase Inhibitors | Maximum Tolerated Dose | Antineoplastic Protocols | Clinical Trial, Phase 1
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-87890387 for Advanced Solid Tumors

Advanced Solid Tumors

United States, France, Spain
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

Neoplasms | Myeloproliferative Disorders | Essential Thrombocythemia | Myelofibrosis

United States, Spain, France, Canada
Merck Sharp & Dohme LLC

Recruiting

A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)

Hepatic Impairment | Non-alcoholic Steatohepatitis

United States
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Lymphoma, Non-Hodgkin | Leukemia, Lymphocytic, Chronic, B-Cell

United States, Korea, Republic of, United Kingdom, Taiwan, Israel, Spain, Australia, France
Janssen Vaccines & Prevention B.V.

Completed

A Study of Ad26.COV2.S Administered as Booster Vaccination in Adults Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2 (Amplify)

Coronavirus Disease

United States
Janssen Scientific Affairs, LLC

Available

Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma

Multiple Myeloma
Janssen Vaccines & Prevention B.V.

Completed

A Study of Ad26.COV2.S in Healthy Adults (COVID-19)

Healthy

Netherlands
Janssen Research & Development, LLC

Completed

A Study of JNJ-64300535 in Healthy Participants

Healthy

Belgium
Janssen Pharmaceutical K.K.

Completed

A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms, Castration-Resistant

Japan
Janssen Research & Development, LLC

Terminated

A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer

Advanced Cancer

United States
Janssen Research & Development, LLC

Terminated

Study to Examine the Cytokine Levels, Gene Expression and Safety of a Single Nasal Dose of JNJ-43260295, in Healthy Participants, and Atopic Participants With Mild to Mild-Persistent Asthma

Healthy | Asthma

United States
Janssen Research & Development, LLC

Terminated

A Study of Rilematovir in Infants and Children and Subsequently in Neonates Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV) (DAISY)

Respiratory Tract Infections

Belgium, Czechia, Taiwan, Japan, Hungary, Thailand, United States, Germany, Korea, Republic of, Turkey, China, Spain, Brazil, Bulgaria, Malaysia, Estonia, Argentina, Poland, Israel, Italy, Latvia, Mexico, Panama, Slovakia, Sweden, Ukraine
Janssen Pharmaceutical K.K.

Completed

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers

Neoplasm

Japan
OHSU Knight Cancer Institute
Oregon Health and Science University; Janssen, LP; The Leukemia and Lymphoma...

Terminated

JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate Safety and Immunogenicity of the ExPEC4V Clinical Trial Material After a Single Intramuscular Dose and a Second Dose 6 Months Later in Healthy Participants Aged 18 Years and Older

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Absorption, Metabolism, and Routes of Excretion Following Oral Administration of (14C) Radiolabeled JNJ--42756493 to Healthy Male Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Characterize the Absorption, Metabolism, and Excretion of 14C-JNJ-53718678 After a Single Oral Dose in Healthy Male Participants

Healthy

Netherlands
Janssen Research & Development, LLC

Completed

Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants

Alzheimer Disease

United States
Janssen Research & Development, LLC

Recruiting

A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer (PolyDamas)

Carcinoma, Non-Small-Cell Lung

Korea, Republic of, United States, Malaysia, Turkey
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Effect of JNJ-63623872 on Cardiac Repolarization Interval in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

The Effects of JNJ-42165279 on the Neural Basis of Anxiety Disorders in Healthy Male Volunteers

Healthy

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults

COVID-19 Prevention

United States, Germany, Brazil, Poland, South Africa
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease (Autonomy)

Cognitive Dysfunction | Dementia | Alzheimer Disease

United States, Belgium, France, Japan, United Kingdom, Spain, Canada, Australia, Sweden, Netherlands
Aragon Pharmaceuticals, Inc.

No longer available

An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms

Colombia, Brazil, Mexico
Janssen Research & Development, LLC

Completed

A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors

Advanced Solid Neoplasms

Spain, Israel
Janssen Pharmaceutical K.K.

Completed

A Study of Ad26.COV2.S in Adults (COVID-19)

Healthy

Japan
Janssen Research & Development, LLC

Withdrawn

A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma (MonumenTAL-5)

Relapsed/ Refractory Multiple Myeloma

United States, Poland
M.D. Anderson Cancer Center

Active, not recruiting

Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Small Cell Neuroendocrine Carcinoma | Metastatic Prostate Adenocarcinoma | Castration-Resistant...

United States
Janssen Research & Development, LLC

Terminated

A Study of JNJ-64140284 Solid Dose Formulations in Healthy Male Participants

Healthy

Belgium
Johnson & Johnson Pharmaceutical Research & Development...

Withdrawn

A Study to Evaluate the Pharmacokinetic Drug Interaction Between Multiple Doses of JNJ-31001074 and a Single Dose of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel in Women

Healthy | Pharmacokinetics | Drug Interactions
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia)

Pain | Mononeuropathies | Neuralgia | Neuralgia, Postherpetic

United States, Spain, Belgium, Netherlands
King's College London

Recruiting

Imaging 5HT7 Antagonist Effects in Bipolar Disorder

Bipolar Disorder

United Kingdom
Janssen Pharmaceutical K.K.

Active, not recruiting

A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Hematologic Malignancies

Japan
Janssen Research & Development, LLC

Active, not recruiting

A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms

China
Janssen Sciences Ireland UC

Completed

A Study to Evaluate the Effect of Hepatic Impairment on JNJ-73763989

Hepatic Impairment

Germany
Janssen Scientific Affairs, LLC

Approved for marketing

Expanded Access Program (EAP) for Participants With Advanced Cancers and Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations Who Have Exhausted All Treatment Options

Advanced Cancers and FGFR Genetic Alterations
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin (JNJ-28431754) in Healthy Indian Volunteers

Healthy

India
Janssen Research & Development, LLC

Terminated

A Study to Investigate Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA Gamma 8) Receptor Occupancy of JNJ-64140284 With Newly Developed Transmembrane AMPA Receptor Regulatory Protein (TARP)-Gamma 8 Positron Emission Tomography (PET) [18F]JNJ-64511070 in Healthy Men

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis

Psoriasis

United States, Poland
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy

Prostate Adenocarcinoma | Stage IIB Prostate Cancer AJCC v8

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants

Obesity

United States, Belgium, United Kingdom, Sweden, Poland, Canada
Janssen Research & Development, LLC

Completed

A Study of Cetrelimab in Participants With Chronic Hepatitis B Virus Infection

Hepatitis B, Chronic

France, Germany, Spain, Poland, Belgium
Janssen Research & Development, LLC

Completed

A Study to Evaluate JNJ-64565111 Pharmacokinetics and Safety in Adult Participants With Varying Degrees of Renal Function

Kidney Failure, Chronic

United States

3

Subscribe